Advanced models for predicting event occurrence in event-driven clinical trials accounting for patient dropout, cure and ongoing recruitment

08/20/2021
by   Vladimir Anisimov, et al.
0

We consider event-driven clinical trials, where the analysis is performed once a pre-determined number of clinical events has been reached. For example, these events could be progression in oncology or a stroke in cardiovascular trials. At the interim stage, one of the main tasks is predicting the number of events over time and the time to reach specific milestones, where we need to account for events that may occur not only in patients already recruited and are followed-up but also in patients yet to be recruited. Therefore, in such trials we need to model patient recruitment and event counts together. In the paper we develop a new analytic approach which accounts for the opportunity of patients to be cured, as well as for them to dropout and be lost to follow-up. Recruitment is modelled using a Poisson-gamma model developed in previous publications. When considering the occurrence of events, we assume that the time to the main event and the time to dropout are independent random variables, and we have developed a few advanced models with cure using exponential, Weibull and log-normal distributions. This technique is supported by well developed, tested and documented software. The results are illustrated using simulation and a real dataset with reference to the developed software.

READ FULL TEXT

page 1

page 2

page 3

page 4

research
02/14/2022

Modelling and forecasting patient recruitment in clinical trials with patients' dropout

This paper focuses on statistical modelling and prediction of patient re...
research
11/02/2021

Comparison of Time-to-First-Event and Recurrent Event Methods in Multiple Sclerosis Trials

Suppression of disability progression is an important goal in the treatm...
research
06/01/2018

Adversity Index for Clinical Trials: An Inclusive Approach for Analysis of Safety Data

This paper proposes a new method for analysis of adverse event data in c...
research
01/11/2023

Pragmatic Estimation of Sample Size for Number of Interviews for PRO development in the 2009 FDA PRO guidance

PROs developed de novo, using the FDA guidance may involve structured pa...
research
12/25/2022

Modeling restricted enrollment and optimal cost-efficient design in multicenter clinical trials

Design and forecasting of patient enrollment is among the greatest chall...
research
12/02/2018

In-silico Risk Analysis of Personalized Artificial Pancreas Controllers via Rare-event Simulation

Modern treatments for Type 1 diabetes (T1D) use devices known as artific...

Please sign up or login with your details

Forgot password? Click here to reset